Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GATA3 Transcription Factor | 1 | 2026 | 44 | 0.940 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2026 | 79 | 0.930 |
Why?
|
| Hemangiosarcoma | 1 | 2026 | 47 | 0.920 |
Why?
|
| Skin Neoplasms | 7 | 2022 | 901 | 0.860 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2024 | 5 | 0.860 |
Why?
|
| Mast Cells | 1 | 2024 | 66 | 0.830 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2020 | 16 | 0.800 |
Why?
|
| Skin | 3 | 2024 | 543 | 0.780 |
Why?
|
| Skin Diseases | 3 | 2022 | 141 | 0.780 |
Why?
|
| Acanthoma | 1 | 2022 | 5 | 0.760 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 15 | 0.750 |
Why?
|
| Biomarkers, Tumor | 3 | 2026 | 1617 | 0.740 |
Why?
|
| Acrospiroma | 1 | 2020 | 4 | 0.650 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 33 | 0.630 |
Why?
|
| Breast Neoplasms | 1 | 2026 | 2613 | 0.400 |
Why?
|
| Melanocytes | 2 | 2022 | 45 | 0.260 |
Why?
|
| Immunohistochemistry | 3 | 2026 | 1612 | 0.260 |
Why?
|
| Biopsy | 4 | 2024 | 1244 | 0.250 |
Why?
|
| Leprosy, Multibacillary | 1 | 2026 | 2 | 0.240 |
Why?
|
| Erythema Nodosum | 1 | 2026 | 3 | 0.240 |
Why?
|
| Leprosy, Lepromatous | 1 | 2026 | 4 | 0.240 |
Why?
|
| Leprostatic Agents | 1 | 2026 | 4 | 0.240 |
Why?
|
| Hypopigmentation | 1 | 2026 | 13 | 0.240 |
Why?
|
| Carcinosarcoma | 2 | 2015 | 11 | 0.220 |
Why?
|
| Tryptases | 1 | 2024 | 17 | 0.210 |
Why?
|
| Urticaria | 1 | 2024 | 18 | 0.210 |
Why?
|
| Dermatitis | 1 | 2024 | 27 | 0.210 |
Why?
|
| Myofibrils | 1 | 2003 | 24 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 989 | 0.200 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 637 | 0.200 |
Why?
|
| MART-1 Antigen | 1 | 2022 | 14 | 0.190 |
Why?
|
| SOXE Transcription Factors | 1 | 2022 | 15 | 0.190 |
Why?
|
| Schwann Cells | 1 | 2002 | 62 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.170 |
Why?
|
| Myoclonus | 1 | 2021 | 32 | 0.170 |
Why?
|
| Scalp | 2 | 2020 | 58 | 0.170 |
Why?
|
| Hidrocystoma | 1 | 2020 | 4 | 0.160 |
Why?
|
| Apocrine Glands | 1 | 2020 | 5 | 0.160 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 2303 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 268 | 0.160 |
Why?
|
| Encephalitis | 1 | 2021 | 122 | 0.160 |
Why?
|
| Melanoma | 2 | 2008 | 925 | 0.160 |
Why?
|
| Barrett Esophagus | 1 | 2003 | 360 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 392 | 0.140 |
Why?
|
| Humans | 19 | 2026 | 130870 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2002 | 685 | 0.140 |
Why?
|
| Cryoglobulinemia | 1 | 2017 | 10 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2026 | 6801 | 0.130 |
Why?
|
| Genome, Human | 2 | 2015 | 1324 | 0.130 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2017 | 66 | 0.130 |
Why?
|
| Penis | 1 | 2017 | 83 | 0.130 |
Why?
|
| Heart | 1 | 2001 | 662 | 0.120 |
Why?
|
| Myocardium | 1 | 2001 | 863 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 173 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 27 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 1230 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 59 | 0.110 |
Why?
|
| Middle Aged | 4 | 2024 | 28517 | 0.100 |
Why?
|
| Female | 10 | 2026 | 70560 | 0.100 |
Why?
|
| Young Adult | 2 | 2026 | 10042 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 176 | 0.100 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2012 | 5 | 0.100 |
Why?
|
| Dermatomycoses | 1 | 2012 | 17 | 0.090 |
Why?
|
| Male | 7 | 2026 | 64772 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 623 | 0.090 |
Why?
|
| Aged | 4 | 2024 | 20974 | 0.080 |
Why?
|
| Mutation | 2 | 2015 | 6140 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2008 | 13 | 0.070 |
Why?
|
| Adult | 4 | 2024 | 31245 | 0.070 |
Why?
|
| Lupus Nephritis | 1 | 2007 | 41 | 0.060 |
Why?
|
| Adolescent | 2 | 2024 | 20820 | 0.060 |
Why?
|
| Mycobacterium leprae | 1 | 2026 | 5 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17673 | 0.060 |
Why?
|
| Minocycline | 1 | 2026 | 43 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 584 | 0.060 |
Why?
|
| Nevus | 1 | 2005 | 34 | 0.060 |
Why?
|
| Connective Tissue Diseases | 1 | 2005 | 32 | 0.060 |
Why?
|
| Prednisone | 1 | 2026 | 239 | 0.060 |
Why?
|
| Rifampin | 1 | 2026 | 122 | 0.060 |
Why?
|
| Hamartoma | 1 | 2005 | 51 | 0.050 |
Why?
|
| Child | 1 | 2024 | 26218 | 0.050 |
Why?
|
| Methotrexate | 1 | 2026 | 337 | 0.050 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2003 | 6 | 0.050 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2002 | 8 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 114 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 97 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2026 | 1170 | 0.050 |
Why?
|
| Neural Crest | 1 | 2002 | 50 | 0.050 |
Why?
|
| Recurrence | 1 | 2026 | 1487 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 105 | 0.040 |
Why?
|
| Actins | 1 | 2003 | 316 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 52 | 0.040 |
Why?
|
| Cadaver | 1 | 2001 | 118 | 0.040 |
Why?
|
| Pigmentation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 2031 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2001 | 167 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 540 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 721 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 603 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1892 | 0.030 |
Why?
|
| CREST Syndrome | 1 | 2017 | 2 | 0.030 |
Why?
|
| Ecchymosis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2017 | 34 | 0.030 |
Why?
|
| Purpura | 1 | 2017 | 25 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2017 | 61 | 0.030 |
Why?
|
| Gestational Age | 1 | 2001 | 1213 | 0.030 |
Why?
|
| Body Weight | 1 | 2001 | 989 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 362 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2017 | 186 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 254 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 58 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2001 | 8509 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4913 | 0.020 |
Why?
|
| Hyperpigmentation | 1 | 2007 | 16 | 0.020 |
Why?
|
| Hydroxychloroquine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2008 | 218 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2007 | 119 | 0.010 |
Why?
|
| Fibrosis | 1 | 2007 | 421 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 278 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2907 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 2483 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 7402 | 0.010 |
Why?
|